Company Overview
The Cooper Companies, Inc. functions as a developer, manufacturer, and marketer of contact lens wearers, operating within the broader healthcare sector specifically in the medical instruments and supplies industry. This positioning within the medical instruments industry provides the firm with a stable demand profile driven by the necessity for vision correction products and surgical tools. The company demonstrates significant scale with a market capitalization of $13.80B and an annual revenue base of $4.15B, supported by a workforce of 15,000 employees. These valuation and revenue figures indicate that the firm holds a substantial position in its niche, commanding a significant market value that reflects confidence in its recurring revenue streams from contact lenses and surgical devices. The size of the operation, evidenced by the 15,000-person employee count, suggests a mature business model capable of sustaining operations across its two primary segments, CooperVision and CooperSurgical, which serve distinct but complementary markets.
Financial Health
The company reported a trailing twelve-month revenue of $4.15B, generating net income of $401.40M and an EBITDA of $1.10B during the same period. The gap between the $4.15B revenue and the $401.40M net income reveals a cost structure where operating expenses, taxes, and interest charges consume approximately 90% of top-line sales before reaching the bottom line. The business generated $367.09M in free cash flow, which provides the organization with considerable financial flexibility to fund capital expenditures, service debt, or pursue strategic acquisitions without immediate reliance on external equity financing. Profitability analysis shows a gross margin of 65.4%, indicating high pricing power and low direct costs relative to sales, while an operating margin of 20.8% demonstrates effective control over administrative and selling expenses. The profit margin stands at 9.7%, which represents the final percentage of revenue retained as profit after all expenses, including interest and taxes, have been deducted. On the balance sheet, total cash holdings of $124.90M are significantly lower than total debt of $2.78B, resulting in a debt-to-equity ratio of 33.20, which characterizes the balance sheet as leveraged rather than conservative. Liquidity is assessed as moderate with a current ratio of 1.34, indicating that the company possesses 1.34 dollars in current assets for every dollar of current liabilities, providing a comfortable buffer for short-term obligations. Management effectiveness is measured by a return on equity of 4.9% and a return on assets of 3.6%, metrics that reveal the efficiency with which shareholder capital and total assets are deployed to generate earnings.
Valuation Assessment
The stock trades with a trailing P/E ratio of 35.18 and a forward P/E of 14.09, a significant disparity that implies the market expects a sharp acceleration in earnings growth or a re-rating of the stock multiple to justify the high current valuation relative to future expectations. The price-to-book ratio is 1.65, indicating that the market values the company at a 65% premium over its net asset book value, suggesting investors are paying for intangible assets, brand strength, and future growth potential rather than just tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 3.32 and an EV/EBITDA of 14.96 suggest that the company is valued highly relative to its sales volume and enterprise earnings before interest, taxes, depreciation, and amortization, reflecting strong profitability despite the high debt load. Price momentum data shows a 52-week high of $89.83 and a 52-week low of $61.78, providing a range within which the stock has fluctuated over the past year. While the exact current price is not listed in the provided facts, the valuation metrics suggest the stock is being priced based on future earnings expectations rather than current depressed levels relative to the 52-week high. The beta value of 1.03 indicates that the stock price volatility is slightly higher than the broader market, moving in tandem with general market fluctuations but with a slight premium in sensitivity to market movements.
Growth & Income
Revenue growth is currently standing at 6.2% year-over-year, while earnings growth is significantly higher at 26.9% year-over-year. This divergence implies that the company is improving its operational efficiency or benefiting from margin expansion that allows net income to grow at a much faster pace than the top line. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all of its earnings to reinvest into business growth, research, and development rather than distributing cash to shareholders. This strategy prioritizes capital allocation toward expanding the contact lens and surgical device portfolios over providing immediate income to investors. The overall growth and income profile is characterized by strong earnings acceleration that outpaces revenue growth, combined with a deliberate reinvestment strategy that forgoes dividend payments to fuel long-term business expansion within the medical instruments and supplies sector.